February 1st 2023
Investigators evaluated whether the availability of the biosimilar infliximab was linked to lower out-of-pocket costs using claims from the IBM MarketScan national data set of commercially insured patients.
January 31st 2023
Shifts towards on-patient and higher-cost therapies have been observed in TNF-alpha inhibitor biosimilar availability. Therefore, the importance of investing in biosimilars is encouraged.
The safety and efficacy of 4 adalimumab biosimilars was compared in a real-life setting in adult patients with IBD switching from the originator for a non-medical reason.
A phase 4, post-marketing surveillance study in Korea provides insight into the safety and efficacy of SB2, an infliximab biosimilar, across a wide range of immune-mediated inflammatory diseases, including rheumatoid arthritis, ulcerative colitis, and ankylosing spondylitis.
Disease-dependent factors, such as a history of adverse reactions to bio-originators and disease activity, influenced patients' acceptance of switching from a biologic to a biosimilar.
Results of the study, which focused on patient-reported outcomes in addition to clinical measurements, mirror findings from other large-scale studies evaluating the safety and efficacy of biosimilars in patients with rheumatoid arthritis.
Although patients with inflammatory conditions reported positive attitudes towards biologic treatment, they were far less familiar with biosimilars, indicating the need for clinicians to provide patient education more effectively.